Type 2 Diabetes, Oral Semaglutide

Topline: Oral Semaglutide Cuts Cardiovascular Events in T2D
In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% compared with placebo.
Oral Semaglutide Cuts MACE Risk in Patients With Type 2 Diabetes
Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, Novo Nordisk expects to file for a label expansion.
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U. Approval
Novo Nordisk: Oral Semaglutide Reduces Risk Of Cardiovascular Events In Phase 3 Trial
Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows
Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. The drug, Rybelsus, helped reduce the risk of these events,
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
Zacks.com on MSN8h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...
Daily12h
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial
According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...
FiercePharma1d
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
BioSpace1d
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Novo's Rybelsus results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...